# Aytu Biopharma, Inc: financial statements, quarterly

AYTU · Nasdaq · CIK 1385818 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/aytu.md) · [Financials](/companies/aytu/financials.md) · [Filings](/companies/aytu/filings.md) · [Insiders](/companies/aytu/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aytu/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [17.8](/filings/0001437749-24-034970.md) | [18.7](/filings/0001437749-25-003568.md) | [14.0](/filings/0001437749-25-016833.md) | [14.6 d](/filings/0001437749-25-029723.md) | [16.6](/filings/0001437749-25-034825.md) | [16.2](/filings/0001437749-26-002804.md) | [18.5](/filings/0001437749-26-016721.md) | [15.1 d](/filings/0001437749-26-030908.md) | [13.9](/filings/0001437749-25-034825.md) | [15.2](/filings/0001437749-26-002804.md) | [12.4](/filings/0001437749-26-016721.md) | [16.1 d](/filings/0001437749-26-030908.md) |
| Cost of revenue | $m | [4.8](/filings/0001437749-24-034970.md) | [4.1](/filings/0001437749-25-003568.md) | [3.7](/filings/0001437749-25-016833.md) | [3.5 d](/filings/0001437749-25-029723.md) | [4.6](/filings/0001437749-25-034825.md) | [5.4](/filings/0001437749-26-002804.md) | [5.6](/filings/0001437749-26-016721.md) | [4.9 d](/filings/0001437749-26-030908.md) | [4.7](/filings/0001437749-25-034825.md) | [5.5](/filings/0001437749-26-002804.md) | [4.8](/filings/0001437749-26-016721.md) | [5.7 d](/filings/0001437749-26-030908.md) |
| Gross profit | $m | [13.0](/filings/0001437749-24-034970.md) | [14.6](/filings/0001437749-25-003568.md) | [10.4](/filings/0001437749-25-016833.md) | [11.1 d](/filings/0001437749-25-029723.md) | [12.0](/filings/0001437749-25-034825.md) | [10.8](/filings/0001437749-26-002804.md) | [12.8](/filings/0001437749-26-016721.md) | [10.3 d](/filings/0001437749-26-030908.md) | [9.2](/filings/0001437749-25-034825.md) | [9.6](/filings/0001437749-26-002804.md) | [7.6](/filings/0001437749-26-016721.md) | [10.4 d](/filings/0001437749-26-030908.md) |
| Research and development | $m | [0.6](/filings/0001437749-24-034970.md) | [0.5](/filings/0001437749-25-003568.md) | [0.6](/filings/0001437749-25-016833.md) | [1.0 d](/filings/0001437749-25-029723.md) | [0.4](/filings/0001437749-25-034825.md) | [0.5](/filings/0001437749-26-002804.md) | [0.2](/filings/0001437749-26-016721.md) | [0.2 d](/filings/0001437749-26-030908.md) | [0.0](/filings/0001437749-25-034825.md) | [0.0](/filings/0001437749-26-002804.md) | [0.0](/filings/0001437749-26-016721.md) | [0.0 d](/filings/0001437749-26-030908.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(0.9)](/filings/0001437749-24-034970.md) | [3.1](/filings/0001437749-25-003568.md) | [(1.6)](/filings/0001437749-25-016833.md) | [(2.3) d](/filings/0001437749-25-029723.md) | [(0.9)](/filings/0001437749-25-034825.md) | [(1.7)](/filings/0001437749-26-002804.md) | [2.4](/filings/0001437749-26-016721.md) | [(7.6) d](/filings/0001437749-26-030908.md) | [(1.5)](/filings/0001437749-25-034825.md) | [(2.0)](/filings/0001437749-26-002804.md) | [(4.1)](/filings/0001437749-26-016721.md) | [(0.8) d](/filings/0001437749-26-030908.md) |
| Interest expense | $m | [1.3](/filings/0001437749-24-034970.md) | [1.3](/filings/0001437749-25-003568.md) | [1.3](/filings/0001437749-25-016833.md) | [1.3 d](/filings/0001437749-25-029723.md) | [1.0](/filings/0001437749-25-034825.md) | [1.1](/filings/0001437749-26-002804.md) | [0.9](/filings/0001437749-26-016721.md) | [0.7 d](/filings/0001437749-26-030908.md) | [0.5](/filings/0001437749-25-034825.md) | [0.6](/filings/0001437749-26-002804.md) | [0.4](/filings/0001437749-26-016721.md) | [0.4 d](/filings/0001437749-26-030908.md) |
| Income tax | $m | [0.0](/filings/0001437749-24-034970.md) | [0.8](/filings/0001437749-25-003568.md) | [0.5](/filings/0001437749-25-016833.md) | [0.8 d](/filings/0001437749-25-029723.md) | [0.4](/filings/0001437749-25-034825.md) | [(0.3)](/filings/0001437749-26-002804.md) | [(0.1)](/filings/0001437749-26-016721.md) | [0.4 d](/filings/0001437749-26-030908.md) | [0.0](/filings/0001437749-25-034825.md) | [0.0](/filings/0001437749-26-002804.md) | [0.0](/filings/0001437749-26-016721.md) | [0.0 d](/filings/0001437749-26-030908.md) |
| Net income | $m | [(8.1)](/filings/0001437749-25-016833.md) | [(0.2)](/filings/0001437749-25-016833.md) | [(2.9)](/filings/0001437749-25-016833.md) | [(4.6) d](/filings/0001437749-25-029723.md) | [1.5](/filings/0001437749-26-016721.md) | [0.8](/filings/0001437749-26-016721.md) | [4.0](/filings/0001437749-26-016721.md) | [(19.8) d](/filings/0001437749-26-030908.md) | [2.0](/filings/0001437749-26-016721.md) | [(10.6)](/filings/0001437749-26-016721.md) | [(5.6)](/filings/0001437749-26-016721.md) | [(0.0) d](/filings/0001437749-26-030908.md) |
| Diluted EPS | $ per share | [(1.48)](/filings/0001437749-24-034970.md) | [(0.04)](/filings/0001437749-25-003568.md) | [(0.52)](/filings/0001437749-25-016833.md) | not reported | [(0.15)](/filings/0001437749-25-034825.md) | [(0.26)](/filings/0001437749-26-002804.md) | [0.21](/filings/0001437749-26-016721.md) | not reported | [(0.08)](/filings/0001437749-25-034825.md) | [(1.05)](/filings/0001437749-26-002804.md) | [(0.53)](/filings/0001437749-26-016721.md) | not reported |
| Basic EPS | $ per share | [(1.48)](/filings/0001437749-24-034970.md) | [(0.04)](/filings/0001437749-25-003568.md) | [(0.52)](/filings/0001437749-25-016833.md) | not reported | [0.24](/filings/0001437749-25-034825.md) | [0.13](/filings/0001437749-26-002804.md) | [0.65](/filings/0001437749-26-016721.md) | not reported | [0.21](/filings/0001437749-25-034825.md) | [(1.05)](/filings/0001437749-26-002804.md) | [(0.53)](/filings/0001437749-26-016721.md) | not reported |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [20.0](/filings/0001558370-23-019015.md) | [19.5](/filings/0001437749-24-004149.md) | [19.8](/filings/0001437749-24-017051.md) | [20.0](/filings/0001437749-25-029723.md) | [20.1](/filings/0001437749-24-034970.md) | [20.4](/filings/0001437749-25-003568.md) | [18.2](/filings/0001437749-25-016833.md) | [31.0](/filings/0001437749-26-030908.md) | [32.6](/filings/0001437749-25-034825.md) | [30.0](/filings/0001437749-26-002804.md) | [26.7](/filings/0001437749-26-016721.md) | [26.3](/filings/0001437749-26-030908.md) |
| Current assets | $m | [70.6](/filings/0001558370-23-019015.md) | [71.4](/filings/0001437749-24-004149.md) | [71.1](/filings/0001437749-24-017051.md) | [61.9](/filings/0001437749-25-029723.md) | not reported | not reported | [72.5](/filings/0001437749-25-016833.md) | [79.2](/filings/0001437749-26-030908.md) | [81.1](/filings/0001437749-25-034825.md) | [76.2](/filings/0001437749-26-002804.md) | [67.3](/filings/0001437749-26-016721.md) | [61.8](/filings/0001437749-26-030908.md) |
| Total assets | $m | [133](/filings/0001558370-23-019015.md) | [131](/filings/0001437749-24-004149.md) | [129](/filings/0001437749-24-017051.md) | [118](/filings/0001437749-25-029723.md) | [116](/filings/0001437749-24-034970.md) | [116](/filings/0001437749-25-003568.md) | [124](/filings/0001437749-25-016833.md) | [124](/filings/0001437749-26-030908.md) | [125](/filings/0001437749-25-034825.md) | [122](/filings/0001437749-26-002804.md) | [112](/filings/0001437749-26-016721.md) | [105](/filings/0001437749-26-030908.md) |
| Current liabilities | $m | [65.5](/filings/0001558370-23-019015.md) | [64.2](/filings/0001437749-24-004149.md) | [83.7](/filings/0001437749-24-017051.md) | [62.2](/filings/0001437749-25-029723.md) | [61.3](/filings/0001437749-24-034970.md) | [64.0](/filings/0001437749-25-003568.md) | [70.7](/filings/0001437749-25-016833.md) | [63.1](/filings/0001437749-26-030908.md) | [66.0](/filings/0001437749-25-034825.md) | [65.6](/filings/0001437749-26-002804.md) | [60.0](/filings/0001437749-26-016721.md) | [54.7](/filings/0001437749-26-030908.md) |
| Total liabilities | $m | [101](/filings/0001558370-23-019015.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Long-term debt | $m | [15.0](/filings/0001558370-23-019015.md) | [15.0](/filings/0001437749-24-004149.md) | [0.0](/filings/0001437749-24-017051.md) | [10.9](/filings/0001437749-25-003568.md) | [10.4](/filings/0001437749-24-034970.md) | [10.0](/filings/0001437749-25-003568.md) | [9.5](/filings/0001437749-25-016833.md) | [10.9](/filings/0001437749-25-029723.md) | [10.4](/filings/0001437749-25-034825.md) | [10.0](/filings/0001437749-26-002804.md) | [9.5](/filings/0001437749-26-016721.md) | [9.1](/filings/0001437749-26-030908.md) |
| Current portion of debt | $m | not reported | [0.0](/filings/0001437749-24-004149.md) | [15.1](/filings/0001437749-24-017051.md) | [1.9](/filings/0001437749-25-003568.md) | [1.9](/filings/0001437749-24-034970.md) | [1.9](/filings/0001437749-25-003568.md) | [1.9](/filings/0001437749-25-016833.md) | [1.9](/filings/0001437749-25-029723.md) | [1.9](/filings/0001437749-25-034825.md) | [1.9](/filings/0001437749-26-002804.md) | [1.9](/filings/0001437749-26-016721.md) | [1.9](/filings/0001437749-26-030908.md) |
| Short-term borrowings | $m | [1.2](/filings/0001558370-23-019015.md) | [1.0](/filings/0001437749-24-004149.md) | [1.6](/filings/0001437749-24-017051.md) | [2.4](/filings/0001437749-25-003568.md) | [4.3](/filings/0001437749-24-034970.md) | [4.0](/filings/0001437749-25-003568.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [32.2](/filings/0001437749-25-016833.md) | [32.9](/filings/0001437749-25-016833.md) | [30.8](/filings/0001437749-25-016833.md) | [27.7](/filings/0001437749-26-030908.md) | [29.8](/filings/0001437749-26-016721.md) | [30.8](/filings/0001437749-26-016721.md) | [34.9](/filings/0001437749-26-016721.md) | [19.0](/filings/0001437749-26-030908.md) | [23.2](/filings/0001437749-26-016721.md) | [14.2](/filings/0001437749-26-016721.md) | [35.1](/filings/0001437749-26-016721.md) | [35.3](/filings/0001437749-26-030908.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt, us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(211)](/filings/0001558370-23-019015.md) | [(135) d](/filings/0001437749-25-003568.md) | [(254) d](/filings/0001437749-25-016833.md) | [(788) d](/filings/0001437749-25-029723.md) | [(1,190)](/filings/0001437749-25-034825.md) | [2,905 d](/filings/0001437749-26-002804.md) | [(6,455) d](/filings/0001437749-26-016721.md) | [2,803 d](/filings/0001437749-26-030908.md) | [(618)](/filings/0001437749-25-034825.md) | [3,675 d](/filings/0001437749-26-002804.md) | [(4,182) d](/filings/0001437749-26-016721.md) | [4,406 d](/filings/0001437749-26-030908.md) |
| Capital expenditure | $k | not reported | not reported | [0.0 d](/filings/0001437749-25-016833.md) | [329 d](/filings/0001437749-25-029723.md) | [136](/filings/0001437749-25-034825.md) | [6.0 d](/filings/0001437749-26-002804.md) | [69.0 d](/filings/0001437749-26-016721.md) | [17.0 d](/filings/0001437749-26-030908.md) | [0.0](/filings/0001437749-25-034825.md) | [17.0 d](/filings/0001437749-26-002804.md) | [0.0 d](/filings/0001437749-26-016721.md) | [12.0 d](/filings/0001437749-26-030908.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets, us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.5](/filings/0001558370-23-019015.md) | [3.1](/filings/0001558370-23-001645.md) | [3.7](/filings/0001558370-23-009367.md) | [5.5](/filings/0001437749-24-034970.md) | [5.5](/filings/0001437749-25-003568.md) | [5.5](/filings/0001437749-25-016833.md) | [9.1](/filings/0001437749-25-034825.md) | [8.5](/filings/0001437749-26-002804.md) | [8.2](/filings/0001437749-26-016721.md) | [19.5](/filings/0001437749-25-034825.md) | [10.0](/filings/0001437749-26-002804.md) | [10.5](/filings/0001437749-26-016721.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 10,866,708 at 2026-09-15, from the cover of the [10-K filed 2026-09-22](/filings/0001437749-26-030908.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. No prices; not investment advice.